Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Inhibitors”

576 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 576 results

Testing effectiveness (Phase 2)UnknownNCT03993626
What this trial is testing

A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer

Who this might be right for
Colorectal Neoplasms Malignant
Celleron Therapeutics Ltd. 55
Testing effectiveness (Phase 2)UnknownNCT05509478
What this trial is testing

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma

Who this might be right for
Biliary Tract Cancer
The First Hospital of Jilin University 46
Testing effectiveness (Phase 2)UnknownNCT03946943
What this trial is testing

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Who this might be right for
Soft Tissue SarcomasUndifferentiated Pleomorphic Sarcoma
Di Wu 25
Testing effectiveness (Phase 2)Study completedNCT04694183
What this trial is testing

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms
Quan Wang 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07297030
What this trial is testing

SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer

Who this might be right for
Rectal Cancer
Sun Yat-sen University 37
Testing effectiveness (Phase 2)Looking for participantsNCT06811844
What this trial is testing

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Who this might be right for
Nasopharyngeal NeoplasmsPD-1 InhibitorInduction Therapy+2 more
The First Affiliated Hospital of Xiamen University 208
Large-scale testing (Phase 3)Looking for participantsNCT04997837
What this trial is testing

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Who this might be right for
Gastric Cancer
Fudan University 433
Testing effectiveness (Phase 2)Active Not RecruitingNCT04181788
What this trial is testing

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Who this might be right for
Advanced MalignanciesNon-small-cell Lung Cancer
Pfizer 155
Not applicableLooking for participantsNCT06635954
What this trial is testing

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Who this might be right for
CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc. 2,000
Testing effectiveness (Phase 2)Study completedNCT03168139
What this trial is testing

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Cancer
TME Pharma AG 20
Not applicableLooking for participantsNCT04892849
What this trial is testing

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

Who this might be right for
HNSCCNSCLCEsophageal Cancer+4 more
University of Erlangen-Nürnberg Medical School 200
Not applicableStudy completedNCT06253364
What this trial is testing

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Who this might be right for
HCCRecurrence
Chen Xiaoping 462
Early research (Phase 1)UnknownNCT05303844
What this trial is testing

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Who this might be right for
Refractory Malignant Ascites
Fudan University 25
Early research (Phase 1)UnknownNCT03966209
What this trial is testing

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Who this might be right for
Hepatocellular CarcinomaLiver Transplantation
Shanghai Zhongshan Hospital 20
Large-scale testing (Phase 3)UnknownNCT04789434
What this trial is testing

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Who this might be right for
Lymphoma, Large B-Cell, DiffuseTransplantationChemotherapy
Ruijin Hospital 94
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06375109
What this trial is testing

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Who this might be right for
Limited-stage Small-cell Lung Cancer
Beijing Chest Hospital, Capital Medical University 60
Large-scale testing (Phase 3)Looking for participantsNCT06794775
What this trial is testing

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

Who this might be right for
Malignant Melanoma Stage III
Hildur Helgadottir 128
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06045195
What this trial is testing

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
University of Cologne 40
Early research (Phase 1)Looking for participantsNCT06377111
What this trial is testing

Test the Benefit of Vitamin B5 in Patients With Melanoma

Who this might be right for
Melanoma (Skin)
University Health Network, Toronto 12
Testing effectiveness (Phase 2)Looking for participantsNCT07230639
What this trial is testing

Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial

Who this might be right for
Neoadjuvant TherapiesImmune Checkpoint TherapyRadiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University 52
Load More Results